Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase

AIDS Research and Human Retroviruses

Volumn 12, Issue 3, 1996, Pages 223-228

  Antonelli, G ^a   Turriziani, O ^b   Verri, A ^c   Narciso, P ^d   Ferri, F ^d   D'Offizi, G ^b   Dianzani, F ^b  

^a UNIVERSITY OF PISA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CNR   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; THYMIDINE KINASE; THYMIDINE PHOSPHATE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS MUTATION;

EID: 0030039293     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.223     Document Type: Article

References (24)

1. Hirsch MS and D'Aquila RT: Therapy for human immunodeficiency virus infection. N Engl J Med 1993;328:1686-1695.
2. Richman DD: Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-1213.
3. Mitsuya HK, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, and Broder S: 3′-Azido-3′-deoxythymidine (BWA A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenophathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-7100.
4. Furman PA, Fyfe JA, Sinclair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, and Barry DV: Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with the human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-8337.
5. Avramis VI, Markson W, Jackson RL, and Gomperts E: Biochemical pharmacology of zidovudine (AZT) in human T-lymphotropic cell (CEM). AIDS 1989;3:417-422.
6. Lowy I, Caruso M, Goff SP, and Klatzmann D: Cellular thymidine kinase activity is required for the inhibition of HIV-1 replication by AZT in lymphocytes. Virology 1994;200:271-275.
7. Avramis VI, Kwock R, Solorzano MM, and Gomperts E: Evidence of in vitro development of drug resistance to azidothymidine in T-lymphotropic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J Acquit Immune Defic Syndr 1993;6:1287-1296.
8. Gollapudi S and Gupta S: Human immunodeficiency virus 1-induced expression of P-glycoprotein. Biochem Biophys Res Commun 1990;171:1002-1007.
9. Antonelli G, Turriziani O, Cianfriglia M, Riva E, Dong G, Fattorossi A, and Dianzani F: Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res Hum Retroviruses 1992;8:1839-1843.
10. Nyce J, Leonard S, Canupp D, Schulz S, and Wong S: Epigenetic mechanism of drug resistance: Drug-induced DNA hypermethylation and drug resistance. Proc Natl Acad Sci USA 1993;90: 2960-2964.
11. Wu S, Liu X, Solorzano MM, Kwock R, and Avramis VI: Development of zidovudine (AZT) resistance in Jurkat cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′ end of human TK gene. J Acquir Immune Defic Syndr Hum Retroviruses 1995;8:1-9.
12. Dianzani F, Antonelli G, Turriziani O, Riva E, Simeoni E, Signoretti C, Strosselli S, and Cianfriglia M: Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Res Hum Retroviruses 1994;10:1471-1478.
13. Plagemann PGV, Wohlhueter RM, and Woffendin C: Nucleoside and nucleobase transport in animal cells. Biochim Biophys Acta 1988;947:405-443.
14. Arnér ES, Valentin A, and Eriksson S: Thymidine and 3′-azido-3′-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. J Biol Chem 1992;267:10968-10975.
15. Arnér ES, Spasokoukotskaja T, and Eriksson S: Selective assay for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem Biophys Res Commun 1992;188:712-718.
16. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;42:961-962.
17. Maga G, Verri A, Bonizzi L, Ponti W, Poli G, Garbesi A, Niccolai D, Spadari S, and Focher F: Lack of stereospecificity of suid pseudorabies virus thymidine kinase. Biochem J 1993;294: 381-385.
18. Dixon M and Webb EC: Enzymes. Longmans, Greene and Co., Ltd., London, 1966.
19. Stretcher BN, Pesce AJ, Frame PT, Greenber KA, and Stain DS: Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 1994;8:763-769.
20. Stretcher BN, Pesce AJ, Frame PT, and Stain DS: Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38:1541-1547.
21. Burger DM, Meenhorst PL, ten Napel CHH, Mulder JW, Neef C, Koks CHW, Bult A, and Beijnen JH: Pharmacokinetics variability of zidovudine in HIV-infected individuals: Subgroup analysis and drug interaction. AIDS 1994;8:1683-1689.
22. Magnani M, Gazzanelli G, Brandi G, Casablanca A, Fraternale A, Chiarantini L, and Rossi L: 2′,3′-Dideoxycytidine induced drug-resistance in human cells. Life Sci (in press).
23. Michie CA, McLean A, Alcock C, and Beverley PCL: Life span of human lymphocyte subsets defined by CD45 isoforms. Nature (London) 1992;360:264-267.
24. Sprent J and Tough DF: Lymphocyte life-span and memory. Science 1994;265:1395-1400.